Skip to main content

The New Epigenome-Editing Approach for Targeting Dysregulated SNCA Expression: Novel Target Validation for Next-Generation Drug Discovery

Publication ,  Conference
Chiba-Falek, O; Tagliafierro, L; Ilich, E; Sriskanda, A; Kantor, B
Published in: MOLECULAR THERAPY
April 22, 2019

Duke Scholars

Published In

MOLECULAR THERAPY

EISSN

1525-0024

ISSN

1525-0016

Publication Date

April 22, 2019

Volume

27

Issue

4

Start / End Page

35 / 35

Location

Washington, DC

Publisher

CELL PRESS

Conference Name

22nd Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT)

Related Subject Headings

  • Biotechnology
  • 3206 Medical biotechnology
  • 3202 Clinical sciences
  • 3105 Genetics
  • 11 Medical and Health Sciences
  • 10 Technology
  • 06 Biological Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chiba-Falek, O., Tagliafierro, L., Ilich, E., Sriskanda, A., & Kantor, B. (2019). The New Epigenome-Editing Approach for Targeting Dysregulated SNCA Expression: Novel Target Validation for Next-Generation Drug Discovery. In MOLECULAR THERAPY (Vol. 27, pp. 35–35). Washington, DC: CELL PRESS.
Chiba-Falek, Ornit, Lidia Tagliafierro, Ekaterina Ilich, Ahila Sriskanda, and Boris Kantor. “The New Epigenome-Editing Approach for Targeting Dysregulated SNCA Expression: Novel Target Validation for Next-Generation Drug Discovery.” In MOLECULAR THERAPY, 27:35–35. CELL PRESS, 2019.
Chiba-Falek O, Tagliafierro L, Ilich E, Sriskanda A, Kantor B. The New Epigenome-Editing Approach for Targeting Dysregulated SNCA Expression: Novel Target Validation for Next-Generation Drug Discovery. In: MOLECULAR THERAPY. CELL PRESS; 2019. p. 35–35.
Chiba-Falek, Ornit, et al. “The New Epigenome-Editing Approach for Targeting Dysregulated SNCA Expression: Novel Target Validation for Next-Generation Drug Discovery.” MOLECULAR THERAPY, vol. 27, no. 4, CELL PRESS, 2019, pp. 35–35.
Chiba-Falek O, Tagliafierro L, Ilich E, Sriskanda A, Kantor B. The New Epigenome-Editing Approach for Targeting Dysregulated SNCA Expression: Novel Target Validation for Next-Generation Drug Discovery. MOLECULAR THERAPY. CELL PRESS; 2019. p. 35–35.

Published In

MOLECULAR THERAPY

EISSN

1525-0024

ISSN

1525-0016

Publication Date

April 22, 2019

Volume

27

Issue

4

Start / End Page

35 / 35

Location

Washington, DC

Publisher

CELL PRESS

Conference Name

22nd Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT)

Related Subject Headings

  • Biotechnology
  • 3206 Medical biotechnology
  • 3202 Clinical sciences
  • 3105 Genetics
  • 11 Medical and Health Sciences
  • 10 Technology
  • 06 Biological Sciences